KEY TAKEAWAYS
- The trial aimed to assess the feasibility and clinical utility of Oncotype DX testing on core biopsy specimens before NAT in operable HR+/HER2- BC pts.
- The study collected clinical and pathological data.
- The study found Oncotype DX testing on core biopsy samples was successful and changed treatment plans for 25% of pts.
Oncotype DX testing may be useful to predict the benefit of neoadjuvant therapy (NAT) in HR+/HER2- breast cancer, but more research is needed.
Researchers aimed to assess the feasibility and clinical utility of Oncotype DX testing on core biopsy specimens before NAT in operable HR+/HER2- breast cancer(BC) patients(pts).
Pts at clinical stage T2-T4 and/or with positive lymph nodes underwent Oncotype DX testing before receiving NAT. Data on clinical and pathological characteristics, treatment plans, and clinical, radiological, and pathological responses were collected.
Of the 48 pts referred to BC Cancer Vancouver for NAT consideration between September 2021 and January 2023, 26 were eligible and enrolled. The success rate of Oncotype DX on core biopsy samples was 96%, with an average turnaround time of 19 days. About 32% of tumors had a Recurrence Score (RS) of 26 or higher, while 4% scored less than 10. The RS led to changes in treatment recommendations for nearly 25% of pts. In total, 33% received neoadjuvant chemotherapy, 54% had neoadjuvant endocrine treatment, and 12.5% proceeded with upfront surgery.
The study found Oncotype DX testing on core biopsy samples was successful and changed treatment plans for 25% of pts with HR+/HER2- tumors.
Source: https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e12595
Clinical Trial: https://www.clinicaltrials.gov/study/NCT03790813
Lidiya Luzhna, Stephen Chia, Mehrnoosh Pauls, and Nathalie LeVasseur. DOI: 10.1200/JCO.2023.41.16_suppl.e12595 Journal of Clinical Oncology 41, no. 16_suppl (June 01, 2023) e12595-e12595.
